Skip to main content
OpenTrials
Completed

NCT Number: NCT00232804

The BRIDGE Registry: Safety and Efficacy Registry of Bx Cypher Stent

The objective of this study is to establish the safety and efficacy of the treatment with Cypher DES in diabetic patients with documented ischemia due to stenosis (small coronary artery 2.5 -3 mm in lumen diameter, with lesion between 15 mm 30 mm in length, ) in native coronary arteries.

The objective of this study is to document that the use of Cypher DES in these diabetic patients undergoing percutaneous revascularization for stenosis is safe.

Safety will be assessed over a period of 12 months.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Université de Lille, Hôpital cardiologique

Lille, 59037, France

About this study

This is a prospective, multicenter, comparative, non randomised, open registry of 1000 patients who will be followed up to 12 months at 100 sites in France.

Patients will be screened according to normal practice and in relation to the inclusion and exclusion criteria. Patients should have a documented ischemia related to the target vessel.

Procedure of stent placement should be done under existing in hospital procedural protocol and care should be taken to follow Cordis instructions as set forth in the Instructions For Use.

Follow up will be done according to normal procedure and the minimum should be a telephone contact at 1, 6 and 12 months.

All data gathered during the enrollment, procedure, follow up and when specific events to the patient may occur, will be entered into the Internet CRF form, by the treating physician or a person from his staff specifically appointed to this task.

Patient enrollment is anticipated to last 8 months.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • NIDDM treated with oral antidiabetics for at least 3 months, or IDDM treated for at least 3 months with documented HbA1C;
  • Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald Classification B I-II) OR patients with documented silent ischemia;
  • Target lesion stenosis is >50% (visual estimate);
  • Target vessel diameter, between 2.5 and 3.0 mm
  • Target lesion length minimum 15 mm and maximum 30mm

Exclusion criteria

  • CK and CK-MB enzymes above normal or elevated troponin level (as determined by site criteria) at the time of treatment;
  • Has unstable angina classified as Braunwald III B and A or C I-II-III, or is having a peri-infarction;
  • Unprotected left main coronary disease with >=50% stenosis;
  • Significant (>50%) stenosis proximal or distal to the target lesion that might impede inflow or runoff and can not be revascularized before or during the index procedure;
  • Have an ostial target lesion;
  • Documented left ventricular ejection fraction <=30%;
  • In-Stent restenosis;
  • Chronic total occlusion.

Treatment and study plan

Bx Cypher stent

Device

Primary outcomes

  1. MACE.

    Time frame: 1, 6, and 12 months post-procedure

Sponsors and collaborators

Lead sponsor

Cordis US Corp.

Industry

Registry information

Official study title

Safety and Efficacy Registry of Bx Cypher Stent in the Revascularisation of Patients With Significant Risk of Restenosis

Important dates

Study start
2002
Study completion
2004
First posted
Oct 5, 2005
Registry last updated
Oct 10, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.